Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2019
Price : $35 *
At a glance
- Drugs Ixekizumab (Primary)
- Indications Pityriasis rubra pilaris
- Focus Therapeutic Use
- 26 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 30 Apr 2018 Planned End Date changed from 31 Dec 2019 to 30 Nov 2019.
- 30 Apr 2018 Status changed from not yet recruiting to recruiting.